Drug-induced parkinsonism (DIP) in patients treated with antipsychotic drugs is considered a form of post-synaptic parkinsonism, caused by D2-receptor blockade. Recent studies, however, carried out on small and heterogeneous patient samples, have shown that DIP may be associated with [123I]FP-CIT single photon emission computed tomography (SPECT) abnormalities, which are markers of dopamine nigrostriatal terminal defect.In the present study, outpatients fulfilling the DSM-IV criteria for schizophrenia and treated with antipsychotics for at least 6months, were enrolled in order to estimate the prevalence of DIP and, among patients with DIP, the prevalence of [123I]FP-CIT SPECT abnormalities. Socio-demographic and clinical variables associated with the presence of DIP and SPECT abnormalities were also assessed.DIP was diagnosed in 149 out of 448 patients with schizophrenia (33%). Age, use of long-acting antipsychotics and a positive family history of parkinsonism were the only demographic variables significantly associated with the development of DIP. Neuroimaging abnormalities were found in 41 of 97 patients who agreed to undergo [123I]FP-CIT SPECT (42%). Only age differentiated this group of patients from those with normal imaging.These preliminary findings suggest that D2-receptor blockade may coexist with a dopamine nigrostriatal terminal defect, as assessed by [123I]FP-CIT SPECT abnormalities, in a relevant proportion of DIP patients. Longitudinal studies should be designed with the aim of improving our understanding of the mechanisms of pre-synaptic abnormalities in DIP patients and identifying specific treatment strategies. © 2012 Elsevier B.V.

[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism / Tinazzi, M.; Cipriani, A.; Matinella, A.; Cannas, A.; Solla, P.; Nicoletti, A.; Zappia, M.; Morgante, L.; Morgante, F.; Pacchetti, C.; Sciarretta, M.; Dallocchio, C.; Rossi, S.; Malentacchi, M.; Ceravolo, R.; Frosini, D.; Sestini, S.; Bovi, T.; Barbui, C.. - In: SCHIZOPHRENIA RESEARCH. - ISSN 0920-9964. - 139:1-3(2012), pp. 40-45. [10.1016/j.schres.2012.06.003]

[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism

Solla P.;
2012-01-01

Abstract

Drug-induced parkinsonism (DIP) in patients treated with antipsychotic drugs is considered a form of post-synaptic parkinsonism, caused by D2-receptor blockade. Recent studies, however, carried out on small and heterogeneous patient samples, have shown that DIP may be associated with [123I]FP-CIT single photon emission computed tomography (SPECT) abnormalities, which are markers of dopamine nigrostriatal terminal defect.In the present study, outpatients fulfilling the DSM-IV criteria for schizophrenia and treated with antipsychotics for at least 6months, were enrolled in order to estimate the prevalence of DIP and, among patients with DIP, the prevalence of [123I]FP-CIT SPECT abnormalities. Socio-demographic and clinical variables associated with the presence of DIP and SPECT abnormalities were also assessed.DIP was diagnosed in 149 out of 448 patients with schizophrenia (33%). Age, use of long-acting antipsychotics and a positive family history of parkinsonism were the only demographic variables significantly associated with the development of DIP. Neuroimaging abnormalities were found in 41 of 97 patients who agreed to undergo [123I]FP-CIT SPECT (42%). Only age differentiated this group of patients from those with normal imaging.These preliminary findings suggest that D2-receptor blockade may coexist with a dopamine nigrostriatal terminal defect, as assessed by [123I]FP-CIT SPECT abnormalities, in a relevant proportion of DIP patients. Longitudinal studies should be designed with the aim of improving our understanding of the mechanisms of pre-synaptic abnormalities in DIP patients and identifying specific treatment strategies. © 2012 Elsevier B.V.
2012
[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism / Tinazzi, M.; Cipriani, A.; Matinella, A.; Cannas, A.; Solla, P.; Nicoletti, A.; Zappia, M.; Morgante, L.; Morgante, F.; Pacchetti, C.; Sciarretta, M.; Dallocchio, C.; Rossi, S.; Malentacchi, M.; Ceravolo, R.; Frosini, D.; Sestini, S.; Bovi, T.; Barbui, C.. - In: SCHIZOPHRENIA RESEARCH. - ISSN 0920-9964. - 139:1-3(2012), pp. 40-45. [10.1016/j.schres.2012.06.003]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/285600
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 27
social impact